Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities

Advanced Drug Delivery Reviews

Volumn 65, Issue 13-14, 2013, Pages 1731-1747

  Kirtane, Ameya R ^a   Kalscheuer, Stephen M ^a   Panyam, Jayanth ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Efflux inhibitors; Efflux transporters; Endocytosis; Excipients; Extracellular matrix; Interstitial fluid pressure; Nanoparticles; Transport barriers; Tumor penetration

Indexed keywords

ENZYME ACTIVITY; ENZYME INHIBITION; GLYCOPROTEINS; NANOPARTICLES; TRANSPORT PROPERTIES; TUMORS;

EFFLUX TRANSPORTER; ENDOCYTOSIS; EXCIPIENTS; EXTRACELLULAR MATRICES; INTERSTITIAL FLUID PRESSURES; TRANSPORT BARRIER; TUMOR PENETRATION;

DRUG DELIVERY;

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLEOMYCIN; COLLAGENASE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; DRUG CARRIER; ELACRIDAR; ETOPOSIDE; EXCIPIENT; GEMCITABINE; HYALURONIDASE; METHOTREXATE; MITOMYCIN; MONOCLONAL ANTIBODY DC101; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; PACLITAXEL; PAZOPANIB; POLYMER; PREDNISOLONE; PREDNISONE; SORAFENIB; SUNITINIB; SURFACTANT; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VINCRISTINE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BLADDER CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER STEM CELL; CARDIOTOXICITY; CELL ORGANELLE; COLORECTAL CANCER; DNA DAMAGE; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG RESISTANCE; DRUG TRANSPORT; ENCAPSULATION; GLIOBLASTOMA; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LUNG CANCER; LUNG SMALL CELL CANCER; NANOTECHNOLOGY; NEOPLASM; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN STRUCTURE; REVIEW; STROMA CELL; TUMOR MICROENVIRONMENT;

ABC; ATP-BINDING CASSETTE; BCRP; BREAST CANCER RESISTANCE PROTEIN; CANCER STEM CELLS; CMC; CRITICAL MICELLAR CONCENTRATION; CSCS; ECM; EFFLUX INHIBITORS; EFFLUX TRANSPORTERS; EGF; EGFR; EMT; ENDOCYTOSIS; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL TO MESENCHYMAL TRANSITION; EXCIPIENTS; EXTRACELLULAR MATRIX; GFP; GREEN FLUORESCENT PROTEIN; HIF; HISTIDINE RICH GLYCOPROTEIN; HLB; HRE; HRG; HYDROPHILIC LIPOPHILIC BALANCE; HYPOXIA INDUCIBLE FACTOR; HYPOXIA RESPONSIVE ELEMENT; IFP; INTERSTITIAL FLUID PRESSURE; MDR; MRP; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN; NANOPARTICLES; NBDS; NPS; NUCLEOTIDE BINDING DOMAINS; P-GLYCOPROTEIN; P-GP; PEG; PHOSPHOINOSITOL-3-KINASE; PI3K; PLGA; POLY(ETHYLENE GLYCOL); POLY(LACTIDE-CO-GLYCOLIDE); TGF Β; TMDS; TRANSFORMING GROWTH FACTOR Β; TRANSMEMBRANE DOMAINS; TRANSPORT BARRIERS; TUMOR PENETRATION; VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR; VEGF; VEGFR;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; DRUG CARRIERS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84888203141     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.09.001     Document Type: Review

References (277)

1. Yap T.A., Carden C.P., Kaye S.B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat. Rev. Cancer 2009, 9:167-181.
2. Takebe N., Harris P.J., Warren R.Q., Ivy S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 2011, 8:97-106.
3. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5:219-234.
4. Harris A.L., Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol. 1992, 31:205-213.
5. Shabbits J.A., Krishna R., Mayer L.D. Molecular and pharmacological strategies to overcome multidrug resistance. Expert Rev. Anticancer Ther. 2001, 1:585-594.
6. Fracasso P.M., Brady M.F., Moore D.H., Walker J.L., Rose P.G., Letvak L., Grogan T.M., McGuire W.P. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J. Clin. Oncol. 2001, 19:2975-2982.
7. Ma M.K., McLeod H.L., Westervelt P., Fracasso P.M. Pharmacokinetic study of infusional valspodar. J. Clin. Pharmacol. 2002, 42:412-418.
8. Patil Y., Sadhukha T., Ma L., Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control. Release 2009, 136:21-29.
9. Kabanov A.V., Batrakova E.V., Alakhov V.Y. Pluronic block copolymers for overcoming drug resistance in cancer. Adv. Drug Deliv. Rev. 2002, 54:759-779.
10. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 2010, 7:653-664.
11. Chung A.S., Lee J., Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 2010, 10:505-514.
12. Heldin C.H., Rubin K., Pietras K., Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat. Rev. Cancer 2004, 4:806-813.
13. Fletcher J.I., Haber M., Henderson M.J., Norris M.D. ABC transporters in cancer: more than just drug efflux pumps. Nat. Rev. Cancer 2010, 10:147-156.
14. Kruh G.D., Belinsky M.G. The MRP family of drug efflux pumps. Oncogene 2003, 22:7537-7552.
15. Dean M., Rzhetsky A., Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001, 11:1156-1166.
16. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 1976, 455:152-162.
17. Dano K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim. Biophys. Acta 1973, 323:466-483.
18. Kartner N., Riordan J.R., Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983, 221:1285-1288.
19. Chen C.J., Chin J.E., Ueda K., Clark D.P., Pastan I., Gottesman M.M., Roninson I.B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47:381-389.
20. Ueda K., Cardarelli C., Gottesman M.M., Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:3004-3008.
21. McGrath T., Center M.S. Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res. 1988, 48:3959-3963.
22. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
23. Leslie E.M., Deeley R.G., Cole S.P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 2005, 204:216-237.
24. Wright S.R., Boag A.H., Valdimarsson G., Hipfner D.R., Campling B.G., Cole S.P., Deeley R.G. Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung. Clin. Cancer Res. 1998, 4:2279-2289.
25. Scheffer G.L., Pijnenborg A.C., Smit E.F., Muller M., Postma D.S., Timens W., van der Valk P., de Vries E.G., Scheper R.J. Multidrug resistance related molecules in human and murine lung. J. Clin. Pathol. 2002, 55:332-339.
26. Peng K.C., Cluzeaud F., Bens M., Duong Van Huyen J.P., Wioland M.A., Lacave R., Vandewalle A. Tissue and cell distribution of the multidrug resistance-associated protein (MRP) in mouse intestine and kidney. J. Histochem. Cytochem. 1999, 47:757-768.
27. Chandra P., Brouwer K.L. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res. 2004, 21:719-735.
28. Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., van De Vijver M.J., Scheper R.J., Schellens J.H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001, 61:3458-3464.
29. Cordon-Cardo C., O'Brien J.P., Boccia J., Casals D., Bertino J.R., Melamed M.R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 1990, 38:1277-1287.
30. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A., van der Valk M.A., Robanus-Maandag E.C.,Riele H.P., et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77:491-502.
31. Schinkel A.H. The physiological function of drug-transporting P-glycoproteins. Semin. Cancer Biol. 1997, 8:161-170.
32. Roger E., Kalscheuer S., Kirtane A., Guru B.R., Grill A.E., Whittum-Hudson J., Panyam J. Folic acid functionalized nanoparticles for enhanced oral drug delivery. Mol. Pharm. 2012, 9:2103-2110.
33. Aller S.G., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., Harrell P.M., Trinh Y.T., Zhang Q., Urbatsch I.L., Chang G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323:1718-1722.
34. Schinkel A.H., Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 2003, 55:3-29.
35. Sauna Z.E., Smith M.M., Muller M., Kerr K.M., Ambudkar S.V. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J. Bioenerg. Biomembr. 2001, 33:481-491.
36. Sauna Z.E., Ambudkar S.V. Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2515-2520.
37. Sauna Z.E., Ambudkar S.V. Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes. J. Biol. Chem. 2001, 276:11653-11661.
38. Altenberg G.A., Vanoye C.G., Horton J.K., Reuss L. Unidirectional fluxes of rhodamine 123 in multidrug-resistant cells: evidence against direct drug extrusion from the plasma membrane. PNAS 1994, 91:4654-4657.
39. Loo T.W., Clarke D.M. Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"?. Biochem. Biophys. Res. Commun. 2005, 329:419-422.
40. Lugo M.R., Sharom F.J. Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site. Biochemistry 2005, 44:643-655.
41. Chavanpatil M.D., Patil Y., Panyam J. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int. J. Pharm. 2006, 320:150-156.
42. Weisburg J.H., Curcio M., Caron P.C., Raghu G., Mechetner E.B., Roepe P.D., Scheinberg D.A. The multidrug resistance phenotype confers immunological resistance. J. Exp. Med. 1996, 183:2699-2704.
43. Weisburg J.H., Roepe P.D., Dzekunov S., Scheinberg D.A. Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells. J. Biol. Chem. 1999, 274:10877-10888.
44. Ruefli A.A., Tainton K.M., Darcy P.K., Smyth M.J., Johnstone R.W. P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ. 2002, 9:1266-1272.
45. Robinson L.J., Roberts W.K., Ling T.T., Lamming D., Sternberg S.S., Roepe P.D. Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry 1997, 36:11169-11178.
46. Sognier M.A., Zhang Y., Eberle R.L., Sweet K.M., Altenberg G.A., Belli J.A. Sequestration of doxorubicin in vesicles in a multidrug-resistant cell line (LZ-100). Biochem. Pharmacol. 1994, 48:391-401.
47. Wasenius V.M., Jekunen A., Monni O., Joensuu H., Aebi S., Howell S.B., Knuutila S. Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes Cancer 1997, 18:286-291.
48. Rao P.H., Houldsworth J., Palanisamy N., Murty V.V., Reuter V.E., Motzer R.J., Bosl G.J., Chaganti R.S. Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Cancer Res. 1998, 58:4260-4263.
49. Rooney P.H., Stevenson D.A., Marsh S., Johnston P.G., Haites N.E., Cassidy J., McLeod H.L. Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors. Cancer Res. 1998, 58:5042-5045.
50. Chin K.V., Chauhan S.S., Pastan I., Gottesman M.M. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ. 1990, 1:361-365.
51. Grogan T.M., Spier C.M., Salmon S.E., Matzner M., Rybski J., Weinstein R.S., Scheper R.J., Dalton W.S. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993, 81:490-495.
52. Abolhoda A., Wilson A.E., Ross H., Danenberg P.V., Burt M., Scotto K.W. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res. 1999, 5:3352-3356.
53. Levchenko A., Mehta B.M., Niu X., Kang G., Villafania L., Way D., Polycarpe D., Sadelain M., Larson S.M. Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:1933-1938.
54. Loscher W., Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005, 2:86-98.
55. Seelig A., Blatter X.L., Wohnsland F. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison. Int. J. Clin. Pharmacol. Ther. 2000, 38:111-121.
56. Baltes S., Gastens A.M., Fedrowitz M., Potschka H., Kaever V., Loscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 2007, 52:333-346.
57. de Graaf D., Sharma R.C., Mechetner E.B., Schimke R.T., Roninson I.B. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:1238-1242.
58. Ellis L.M., Hicklin D.J. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin. Cancer Res. 2009, 15:7471-7478.
59. Ono M., Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin. Cancer Res. 2006, 12:7242-7251.
60. Bianco R., Troiani T., Tortora G., Ciardiello F. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocr. Relat. Cancer 2005, 12(Suppl. 1):S159-S171.
61. Ware K.E., Marshall M.E., Heasley L.R., Marek L., Hinz T.K., Hercule P., Helfrich B.A., Doebele R.C., Heasley L.E. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS One 2010, 5:e14117.
62. Balendiran G.K., Dabur R., Fraser D. The role of glutathione in cancer. Cell Biochem. Funct. 2004, 22:343-352.
63. Tew K.D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994, 54:4313-4320.
64. Townsend D.M., Tew K.D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003, 22:7369-7375.
65. Mellish K.J., Kelland L.R., Harrap K.R. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br. J. Cancer 1993, 68:240-250.
66. Zamble D.B., Lippard S.J. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem. Sci. 1995, 20:435-439.
67. Martin L.P., Hamilton T.C., Schilder R.J. Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res. 2008, 14:1291-1295.
68. Kaina B., Christmann M. DNA repair in resistance to alkylating anticancer drugs. Int. J. Clin. Pharmacol. Ther. 2002, 40:354-367.
69. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., Visvader J., Weissman I.L., Wahl G.M. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006, 66:9339-9344.
70. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
71. Trumpp A., Wiestler O.D. Mechanisms of disease: cancer stem cells-targeting the evil twin. Nat. Clin. Pract. Oncol. 2008, 5:337-347.
72. Pan C.X., Zhu W., Cheng L. Implications of cancer stem cells in the treatment of cancer. Future Oncol. 2006, 2:723-731.
73. Moserle L., Indraccolo S., Ghisi M., Frasson C., Fortunato E., Canevari S., Miotti S., Tosello V., Zamarchi R., Corradin A., Minuzzo S., Rossi E., Basso G., Amadori A. The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res. 2008, 68:5658-5668.
74. Abubaker K., Latifi A., Luwor R., Nazaretian S., Zhu H., Quinn M.A., Thompson E.W., Findlay J.K., Ahmed N. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Mol. Cancer 2013, 12:24.
75. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
76. Li L., Bhatia R. Stem cell quiescence. Clin. Cancer Res. 2011, 17:4936-4941.
77. Baldini N., Scotlandi K., Barbanti-Brodano G., Manara M.C., Maurici D., Bacci G., Bertoni F., Picci P., Sottili S., Campanacci M., et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N. Engl. J. Med. 1995, 333:1380-1385.
78. Gregorcyk S., Kang Y., Brandt D., Kolm P., Singer G., Perry R.R. p-Glycoprotein expression as a predictor of breast cancer recurrence. Ann. Surg. Oncol. 1996, 3:8-14.
79. Trock B.J., Leonessa F., Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J. Natl. Cancer Inst. 1997, 89:917-931.
80. Agarwal R., Kaye S.B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 2003, 3:502-516.
81. Persidis A. Cancer multidrug resistance. Nat. Biotechnol. 1999, 17:94-95.
82. Chintamani, Singh J., Mittal M., Saxena S., Bansal A., Bhatia A., Kulshreshtha P. Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer-a prospective clinical study. World J. Surg. Oncol. 2005, 3:61.
83. Karaszi E., Jakab K., Homolya L., Szakacs G., Hollo Z., Telek B., Kiss A., Rejto L., Nahajevszky S., Sarkadi B., Kappelmayer J. Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia. Br. J. Haematol. 2001, 112:308-314.
84. Leith C.P., Kopecky K.J., Godwin J., McConnell T., Slovak M.L., Chen I.M., Head D.R., Appelbaum F.R., Willman C.L. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997, 89:3323-3329.
85. Cleary I., Doherty G., Moran E., Clynes M. The multidrug-resistant human lung tumour cell line, DLKP-A10, expresses novel drug accumulation and sequestration systems. Biochem. Pharmacol. 1997, 53:1493-1502.
86. Breuninger L.M., Paul S., Gaughan K., Miki T., Chan A., Aaronson S.A., Kruh G.D. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 1995, 55:5342-5347.
87. Ma L., Center M.S. The gene encoding vacuolar H(+)-ATPase subunit C is overexpressed in multidrug-resistant HL60 cells. Biochem. Biophys. Res. Commun. 1992, 182:675-681.
88. Martinez-Zaguilan R., Raghunand N., Lynch R.M., Bellamy W., Martinez G.M., Rojas B., Smith D., Dalton W.S., Gillies R.J. pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. Biochem. Pharmacol. 1999, 57:1037-1046.
89. Raghunand N., Martinez-Zaguilan R., Wright S.H., Gillies R.J. pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem. Pharmacol. 1999, 57:1047-1058.
90. Jain R.K. The next frontier of molecular medicine: delivery of therapeutics. Nat. Med. 1998, 4:655-657.
91. Tredan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99:1441-1454.
92. Primeau A.J., Rendon A., Hedley D., Lilge L., Tannock I.F. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin. Cancer Res. 2005, 11:8782-8788.
93. Milane L., Duan Z., Amiji M. Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell Int. 2011, 11:3.
94. Starling E.H. On the absorption of fluids from the connective tissue spaces. J. Physiol. 1896, 19:312-326.
95. Aukland K., Reed R.K. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol. Rev. 1993, 73:1-78.
96. Wiig H., Rubin K., Reed R.K. New and active role of the interstitium in control of interstitial fluid pressure: potential therapeutic consequences. Acta Anaesthesiol. Scand. 2003, 47:111-121.
97. Minchinton A.I., Tannock I.F. Drug penetration in solid tumours. Nat. Rev. Cancer 2006, 6:583-592.
98. Jain R.K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987, 6:559-593.
99. Jain R.K. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987, 47:3039-3051.
100. Stanczyk M., Olszewski W.L., Gewartowska M., Domaszewska-Szostek A. Lack of functioning lymphatics and accumulation of tissue fluid/lymph in interstitial "lakes" in colon cancer tissue. Lymphology 2010, 43:158-167.
101. Boucher Y., Baxter L.T., Jain R.K. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 1990, 50:4478-4484.
102. Stanczyk M., Olszewski W.L., Gewartowska M., Domaszewska-Szostek A. Lack of functioning lymphatics and accumulation of tissue fluid/lymph in interstitial "lakes" in colon cancer tissue. Lymphology 2010, 43:158-167.
103. Olszewski W.L., Stanczyk M., Gewartowska M., Domaszewska-Szostek A., Durlik M. Lack of functioning intratumoral lymphatics in colon and pancreas cancer tissue. Lymphat. Res. Biol. 2012, 10:112-117.
104. Gullino D., Masenti E., Trotti-Maina G. Primary tumors of the pleura. II. Submesothelial tumors. (Anatomo-clinical considerations on 21 cases). Arch. Chir. Torac. Cardiovasc. 1968, 25:83-115.
105. Hagendoorn J., Tong R., Fukumura D., Lin Q., Lobo J., Padera T.P., Xu L., Kucherlapati R., Jain R.K. Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res. 2006, 66:3360-3364.
106. Goel S., Duda D.G., Xu L., Munn L.L., Boucher Y., Fukumura D., Jain R.K. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 2011, 91:1071-1121.
107. Jain R.K. Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1999, 1:241-263.
108. Brannon-Peppas L., Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 2004, 56:1649-1659.
109. Narang A.S., Varia S. Role of tumor vascular architecture in drug delivery. Adv. Drug Deliv. Rev. 2011, 63:640-658.
110. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
111. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
112. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
113. Young J.S., Lumsden C.E., Stalker A.L. The significance of the tissue pressure of normal testicular and of neoplastic (Brown-Pearce carcinoma) tissue in the rabbit. J. Pathol. Bacteriol. 1950, 62:313-333.
114. Roh H.D., Boucher Y., Kalnicki S., Buchsbaum R., Bloomer W.D., Jain R.K. Interstitial hypertension in carcinoma of uterine cervix in patients: possible correlation with tumor oxygenation and radiation response. Cancer Res. 1991, 51:6695-6698.
115. Boucher Y., Kirkwood J.M., Opacic D., Desantis M., Jain R.K. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res. 1991, 51:6691-6694.
116. Boucher Y., Jain R.K. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res. 1992, 52:5110-5114.
117. Curti B.D., Urba W.J., Alvord W.G., Janik J.E., Smith J.W., Madara K., Longo D.L. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res. 1993, 53:2204-2207.
118. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., Yamauchi M., Gasser D.L., Weaver V.M. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
119. Holback H., Yeo Y. Intratumoral drug delivery with nanoparticulate carriers. Pharm. Res. 2011, 28:1819-1830.
120. Hinz B. The myofibroblast: paradigm for a mechanically active cell. J. Biomech. 2010, 43:146-155.
121. Larsen M., Artym V.V., Green J.A., Yamada K.M. The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr. Opin. Cell Biol. 2006, 18:463-471.
122. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 2012, 196:395-406.
123. Sabeh F., Shimizu-Hirota R., Weiss S.J. Protease-dependent versus-independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J. Cell Biol. 2009, 185:11-19.
124. Green C.E., Liu T., Montel V., Hsiao G., Lester R.D., Subramaniam S., Gonias S.L., Klemke R.L. Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization. PLoS One 2009, 4:e6713.
125. Bristow R.G., Hill R.P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer 2008, 8:180-192.
126. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 2001, 93:266-276.
127. Shannon A.M., Bouchier-Hayes D.J., Condron C.M., Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat. Rev. 2003, 29:297-307.
128. Cunningham M.L., Ringrose P.S., Lokesh B.R. Inhibition of the genotoxicity of bleomycin by superoxide dismutase. Mutat. Res. 1984, 135:199-202.
129. Freitas I. Role of hypoxia in photodynamic therapy of tumors. Tumori 1985, 71:251-259.
130. Amellem O., Pettersen E.O. Cell inactivation and cell cycle inhibition as induced by extreme hypoxia: the possible role of cell cycle arrest as a protection against hypoxia-induced lethal damage. Cell Prolif. 1991, 24:127-141.
131. Huang L.E., Arany Z., Livingston D.M., Bunn H.F. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J. Biol. Chem. 1996, 271:32253-32259.
132. Huang L.E., Gu J., Schau M., Bunn H.F. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:7987-7992.
133. Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002, 62:3387-3394.
134. Koppenol W.H., Bounds P.L., Dang C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 2011, 11:325-337.
135. Racker E. Bioenergetics and the problem of tumor growth. Am. Sci. 1972, 60:56-63.
136. Raghunand N., Gillies R.J. pH and drug resistance in tumors. Drug Resist. Updat. 2000, 3:39-47.
137. Jabr-Milane L.S., van Vlerken L.E., Yadav S., Amiji M.M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev. 2008, 34:592-602.
138. Kataoka K., Harada A., Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 2001, 47:113-131.
139. Chavanpatil M.D., Khdair A., Panyam J. Surfactant-polymer nanoparticles: a novel platform for sustained and enhanced cellular delivery of water-soluble molecules. Pharm. Res. 2007, 24:803-810.
140. Sahoo S.K., Panyam J., Prabha S., Labhasetwar V. Residual polyvinyl alcohol associated with poly (d, l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Control. Release 2002, 82:105-114.
141. Sadhukha T., Wiedmann T.S., Panyam J. Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy. Biomaterials 2013, 34:5163-5174.
142. Lawrence M.J. Surfactant systems: microemulsions and vesicles as vehicles for drug delivery. Eur. J. Drug Metab. Pharmacokinet. 1994, 19:257-269.
143. Torchilin V.P. Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Release 2001, 73:137-172.
144. Riehm H., Biedler J.L. Potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin D and daunomycin. Cancer Res. 1972, 32:1195-1200.
145. Dong X., Mumper R.J. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond.) 2010, 5:597-615.
146. Woodcock D.M., Jefferson S., Linsenmeyer M.E., Crowther P.J., Chojnowski G.M., Williams B., Bertoncello I. Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res. 1990, 50:4199-4203.
147. Woodcock D.M., Linsenmeyer M.E., Chojnowski G., Kriegler A.B., Nink V., Webster L.K., Sawyer W.H. Reversal of multidrug resistance by surfactants. Br. J. Cancer 1992, 66:62-68.
148. Gelderblom H., Verweij J., Nooter K., Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 2001, 37:1590-1598.
149. Sakai T., Alexandridis P. Single-step synthesis and stabilization of metal nanoparticles in aqueous pluronic block copolymer solutions at ambient temperature. Langmuir 2004, 20:8426-8430.
150. Oh K.S., Song J.Y., Cho S.H., Lee B.S., Kim S.Y., Kim K., Jeon H., Kwon I.C., Yuk S.H. Paclitaxel-loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy. J. Control. Release 2010, 148:344-350.
151. Kabanov A.V., Alakhov V.Y. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit. Rev. Ther. Drug Carrier Syst. 2002, 19:1-72.
152. Batrakova E.V., Li S., Elmquist W.F., Miller D.W., Alakhov V.Y., Kabanov A.V. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion. Br. J. Cancer 2001, 85:1987-1997.
153. Batrakova E.V., Li S., Vinogradov S.V., Alakhov V.Y., Miller D.W., Kabanov A.V. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J. Pharmacol. Exp. Ther. 2001, 299:483-493.
154. Valle J.W., Armstrong A., Newman C., Alakhov V., Pietrzynski G., Brewer J., Campbell S., Corrie P., Rowinsky E.K., Ranson M. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest. New Drugs 2011, 29:1029-1037.
155. Coon J.S., Knudson W., Clodfelter K., Lu B., Weinstein R.S. Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance. Cancer Res. 1991, 51:897-902.
156. Koziara J.M., Whisman T.R., Tseng M.T., Mumper R.J. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J. Control. Release 2006, 112:312-319.
157. Koziara J.M., Lockman P.R., Allen D.D., Mumper R.J. Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Control. Release 2004, 99:259-269.
158. Dong X., Mattingly C.A., Tseng M.T., Cho M.J., Liu Y., Adams V.R., Mumper R.J. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res. 2009, 69:3918-3926.
159. Bogman K., Erne-Brand F., Alsenz J., Drewe J. The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. J. Pharm. Sci. 2003, 92:1250-1261.
160. Buckingham L.E., Balasubramanian M., Emanuele R.M., Clodfelter K.E., Coon J.S. Comparison of solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents. Int. J. Cancer 1995, 62:436-442.
161. Lo Y.L. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J. Control. Release 2003, 90:37-48.
162. Vauthier C., Dubernet C., Chauvierre C., Brigger I., Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J. Control. Release 2003, 93:151-160.
163. Cuvier C., Roblot-Treupel L., Millot J.M., Lizard G., Chevillard S., Manfait M., Couvreur P., Poupon M.F. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem. Pharmacol. 1992, 44:509-517.
164. Treupel L., Poupon M.F., Couvreur P., Puisieux F. Vectorisation of doxorubicin in nanospheres and reversion of pleiotropic resistance of tumor cells. C. R. Acad. Sci. III 1991, 313:171-174.
165. de Verdiere A.C., Dubernet C., Nemati F., Soma E., Appel M., Ferte J., Bernard S., Puisieux F., Couvreur P. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br. J. Cancer 1997, 76:198-205.
166. Barraud L., Merle P., Soma E., Lefrancois L., Guerret S., Chevallier M., Dubernet C., Couvreur P., Trepo C., Vitvitski L. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J. Hepatol. 2005, 42:736-743.
167. Hugger E.D., Audus K.L., Borchardt R.T. Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J. Pharm. Sci. 2002, 91:1980-1990.
168. Wang J., Qu H., Jin L., Zeng W., Qin L., Zhang F., Wei X., Lu W., Zhang C., Liang W. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells. J. Pharm. Sci. 2011, 100:2267-2277.
169. Johnson B.M., Charman W.N., Porter C.J. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci 2002, 4:E40.
170. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2003, 2:214-221.
171. Shen Q., Lin Y., Handa T., Doi M., Sugie M., Wakayama K., Okada N., Fujita T., Yamamoto A. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int. J. Pharm. 2006, 313:49-56.
172. Kopecek J., Kopeckova P., Minko T., Lu Z.R., Peterson C.M. Water soluble polymers in tumor targeted delivery. J. Control. Release 2001, 74:147-158.
173. Panyam J., Zhou W.Z., Prabha S., Sahoo S.K., Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002, 16:1217-1226.
174. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003, 55:329-347.
175. Murakami M., Cabral H., Matsumoto Y., Wu S., Kano M.R., Yamori T., Nishiyama N., Kataoka K. Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci. Transl. Med. 2011, 3:64ra2.
176. Bareford L.M., Swaan P.W. Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 2007, 59:748-758.
177. Thierry A.R., Vige D., Coughlin S.S., Belli J.A., Dritschilo A., Rahman A. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J. 1993, 7:572-579.
178. Colin de Verdiere A., Dubernet C., Nemati F., Poupon M.F., Puisieux F., Couvreur P. Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells. Cancer Chemother. Pharmacol. 1994, 33:504-508.
179. Wong H.L., Bendayan R., Rauth A.M., Xue H.Y., Babakhanian K., Wu X.Y. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J. Pharmacol. Exp. Ther. 2006, 317:1372-1381.
180. Wong H.L., Rauth A.M., Bendayan R., Manias J.L., Ramaswamy M., Liu Z., Erhan S.Z., Wu X.Y. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm. Res. 2006, 23:1574-1585.
181. Chavanpatil M.D., Khdair A., Gerard B., Bachmeier C., Miller D.W., Shekhar M.P., Panyam J. Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. Mol. Pharm. 2007, 4:730-738.
182. Omelyanenko V., Kopeckova P., Gentry C., Kopecek J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J. Control. Release 1998, 53:25-37.
183. Chan Y., Wong T., Byrne F., Kavallaris M., Bulmus V. Acid-labile core cross-linked micelles for pH-triggered release of antitumor drugs. Biomacromolecules 2008, 9:1826-1836.
184. Lee E.S., Na K., Bae Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J. Control. Release 2005, 103:405-418.
185. Ahmed F., Pakunlu R.I., Srinivas G., Brannan A., Bates F., Klein M.L., Minko T., Discher D.E. Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: pH-triggered release through copolymer degradation. Mol. Pharm. 2006, 3:340-350.
186. Guo X., Szoka F.C. Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG-diortho ester-lipid conjugate. Bioconjug. Chem. 2001, 12:291-300.
187. Wang F., Wang Y.C., Dou S., Xiong M.H., Sun T.M., Wang J. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano 2011, 5:3679-3692.
188. Kievit F.M., Wang F.Y., Fang C., Mok H., Wang K., Silber J.R., Ellenbogen R.G., Zhang M. Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. J. Control. Release 2011, 152:76-83.
189. Wang Y., Chen L., Ding Y., Yan W. Oxidized phospholipid based pH sensitive micelles for delivery of anthracyclines to resistant leukemia cells in vitro. Int. J. Pharm. 2012, 422:409-417.
190. Gerasimov O.V., Boomer J.A., Qualls M.M., Thompson D.H. Cytosolic drug delivery using pH- and light-sensitive liposomes. Adv. Drug Deliv. Rev. 1999, 38:317-338.
191. Gao Y., Chen Y., Ji X., He X., Yin Q., Zhang Z., Shi J., Li Y. Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles. ACS Nano 2011, 5:9788-9798.
192. Ferry D.R., Traunecker H., Kerr D.J. Clinical trials of P-glycoprotein reversal in solid tumours. Eur. J. Cancer 1996, 32A:1070-1081.
193. Leonard G.D., Fojo T., Bates S.E. The role of ABC transporters in clinical practice. Oncologist 2003, 8:411-424.
194. List A.F., Kopecky K.J., Willman C.L., Head D.R., Persons D.L., Slovak M.L., Dorr R., Karanes C., Hynes H.E., Doroshow J.H., Shurafa M., Appelbaum F.R. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001, 98:3212-3220.
195. Twentyman P.R., Bleehen N.M. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. Eur. J. Cancer 1991, 27:1639-1642.
196. Oza A.M. Clinical development of P glycoprotein modulators in oncology. Novartis Found. Symp. 2002, 243:103-115. (discussion 115-108, 180-105).
197. Hubensack M., Muller C., Hocherl P., Fellner S., Spruss T., Bernhardt G., Buschauer A. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J. Cancer Res. Clin. Oncol. 2008, 134:597-607.
198. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 2006, 112:457-473.
199. Song X.R., Zheng Y., He G., Yang L., Luo Y.F., He Z.Y., Li S.Z., Li J.M., Yu S., Luo X., Hou S.X., Wei Y.Q. Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma. J. Pharm. Sci. 2010, 99:4874-4879.
200. Song X.R., Cai Z., Zheng Y., He G., Cui F.Y., Gong D.Q., Hou S.X., Xiong S.J., Lei X.J., Wei Y.Q. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur. J. Pharm. Sci. 2009, 37:300-305.
201. Wong H.L., Bendayan R., Rauth A.M., Wu X.Y. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J. Control. Release 2006, 116:275-284.
202. Meng H., Mai W.X., Zhang H., Xue M., Xia T., Lin S., Wang X., Zhao Y., Ji Z., Zink J.I., Nel A.E. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 2013, 7:994-1005.
203. Yadav S., van Vlerken L.E., Little S.R., Amiji M.M. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother. Pharmacol. 2009, 63:711-722.
204. Patil Y.B., Swaminathan S.K., Sadhukha T., Ma L., Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 2010, 31:358-365.
205. Li S.D., Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 2008, 5:496-504.
206. Van der Veldt A.A., Lubberink M., Bahce I., Walraven M., de Boer M.P., Greuter H.N., Hendrikse N.H., Eriksson J., Windhorst A.D., Postmus P.E., Verheul H.M., Serne E.H., Lammertsma A.A., Smit E.F. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012, 21:82-91.
207. Dickson P.V., Hamner J.B., Sims T.L., Fraga C.H., Ng C.Y., Rajasekeran S., Hagedorn N.L., McCarville M.B., Stewart C.F., Davidoff A.M. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin. Cancer Res. 2007, 13:3942-3950.
208. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8:579-591.
209. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., Chung D.C., Sahani D.V., Kalva S.P., Kozin S.V., Mino M., Cohen K.S., Scadden D.T., Hartford A.C., Fischman A.J., Clark J.W., Ryan D.P., Zhu A.X., Blaszkowsky L.S., Chen H.X., Shellito P.C., Lauwers G.Y., Jain R.K. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004, 10:145-147.
210. Wildiers H., Guetens G., De Boeck G., Verbeken E., Landuyt B., Landuyt W., de Bruijn E.A., van Oosterom A.T. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer 2003, 88:1979-1986.
211. Monsky W.L., Fukumura D., Gohongi T., Ancukiewcz M., Weich H.A., Torchilin V.P., Yuan F., Jain R.K. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 1999, 59:4129-4135.
212. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41:189-207.
213. Yuan F., Chen Y., Dellian M., Safabakhsh N., Ferrara N., Jain R.K. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:14765-14770.
214. Miles D.W., Chan A., Dirix L.Y., Cortes J., Pivot X., Tomczak P., Delozier T., Sohn J.H., Provencher L., Puglisi F., Harbeck N., Steger G.G., Schneeweiss A., Wardley A.M., Chlistalla A., Romieu G. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 2010, 28:3239-3247.
215. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000, 5(Suppl. 1):3-10.
216. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct. Funct. 2001, 26:25-35.
217. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
218. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004, 3:391-400.
219. Hurwitz H.I., Fehrenbacher L., Hainsworth J.D., Heim W., Berlin J., Holmgren E., Hambleton J., Novotny W.F., Kabbinavar F. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. 2005, 23:3502-3508.
220. Zakarija A., Soff G. Update on angiogenesis inhibitors. Curr. Opin. Oncol. 2005, 17:578-583.
221. Quesada A.R., Munoz-Chapuli R., Medina M.A. Anti-angiogenic drugs: from bench to clinical trials. Med. Res. Rev. 2006, 26:483-530.
222. Jain R.K., Duda D.G., Clark J.W., Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 2006, 3:24-40.
223. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
224. Gimbrone M.A., Leapman S.B., Cotran R.S., Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 1972, 136:261-276.
225. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
226. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2002, 2:727-739.
227. Le Serve A.W., Hellmann K. Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action. Br. Med. J. 1972, 1:597-601.
228. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004, 64:3731-3736.
229. Cairns R., Papandreou I., Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol. Cancer Res. 2006, 4:61-70.
230. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 2001, 37(Suppl. 4):S9-S15.
231. Maity A., Pore N., Lee J., Solomon D., O'Rourke D.M. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. Cancer Res. 2000, 60:5879-5886.
232. Goldman C.K., Kim J., Wong W.L., King V., Brock T., Gillespie G.Y. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol. Biol. Cell 1993, 4:121-133.
233. Cerniglia G.J., Pore N., Tsai J.H., Schultz S., Mick R., Choe R., Xing X., Durduran T., Yodh A.G., Evans S.M., Koch C.J., Hahn S.M., Quon H., Sehgal C.M., Lee W.M., Maity A. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One 2009, 4:e6539.
234. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., Au H.J., Murawa P., Walde D., Wolff R.A., Campos D., Lim R., Ding K., Clark G., Voskoglou-Nomikos T., Ptasynski M., Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25:1960-1966.
235. Krause M., Baumann M. Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. Cancer Metastasis Rev. 2008, 27:387-402.
236. Fan Z., Baselga J., Masui H., Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993, 53:4637-4642.
237. Ciardiello F., Bianco R., Damiano V., De Lorenzo S., Pepe S., De Placido S., Fan Z., Mendelsohn J., Bianco A.R., Tortora G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res. 1999, 5:909-916.
238. Baselga J., Norton L., Masui H., Pandiella A., Coplan K., Miller W.H., Mendelsohn J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst. 1993, 85:1327-1333.
239. Qayum N., Im J., Stratford M.R., Bernhard E.J., McKenna W.G., Muschel R.J. Modulation of the tumor microvasculature by phosphoinositide-3 kinase inhibition increases doxorubicin delivery in vivo. Clin. Cancer Res. 2012, 18:161-169.
240. Yin M.B., Li Z.R., Toth K., Cao S., Durrani F.A., Hapke G., Bhattacharya A., Azrak R.G., Frank C., Rustum Y.M. Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis. Oncogene 2006, 25:2509-2519.
241. Fakih M.G., Pendyala L., Smith P.F., Creaven P.J., Reid M.E., Badmaev V., Azrak R.G., Prey J.D., Lawrence D., Rustum Y.M. A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors. Clin. Cancer Res. 2006, 12:1237-1244.
242. Cao S., Durrani F.A., Rustum Y.M. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin. Cancer Res. 2004, 10:2561-2569.
243. Bhattacharya A., Seshadri M., Oven S.D., Toth K., Vaughan M.M., Rustum Y.M. Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs. Clin. Cancer Res. 2008, 14:3926-3932.
244. Escorcia F.E., Henke E., McDevitt M.R., Villa C.H., Smith-Jones P., Blasberg R.G., Benezra R., Scheinberg D.A. Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res. 2010, 70:9277-9286.
245. Sorensen A.G., Emblem K.E., Polaskova P., Jennings D., Kim H., Ancukiewicz M., Wang M., Wen P.Y., Ivy P., Batchelor T.T., Jain R.K. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2012, 72:402-407.
246. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., Xu L., Hicklin D.J., Fukumura D., di Tomaso E., Munn L.L., Jain R.K. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
247. Rolny C., Mazzone M., Tugues S., Laoui D., Johansson I., Coulon C., Squadrito M.L., Segura I., Li X., Knevels E., Costa S., Vinckier S., Dresselaer T., Akerud P., De Mol M., Salomaki H., Phillipson M., Wyns S., Larsson E., Buysschaert I., Botling J., Himmelreich U., Van Ginderachter J.A., De Palma M., Dewerchin M., Claesson-Welsh L., Carmeliet P. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011, 19:31-44.
248. Huang Y., Snuderl M., Jain R.K. Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity. Cancer Cell 2011, 19:1-2.
249. Jain R.K., Baxter L.T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988, 48:7022-7032.
250. Vlahovic G., Ponce A.M., Rabbani Z., Salahuddin F.K., Zgonjanin L., Spasojevic I., Vujaskovic Z., Dewhirst M.W. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br. J. Cancer 2007, 97:735-740.
251. Tailor T.D., Hanna G., Yarmolenko P.S., Dreher M.R., Betof A.S., Nixon A.B., Spasojevic I., Dewhirst M.W. Effect of pazopanib on tumor microenvironment and liposome delivery. Mol. Cancer Ther. 2010, 9:1798-1808.
252. Chauhan V.P., Stylianopoulos T., Martin J.D., Popovic Z., Chen O., Kamoun W.S., Bawendi M.G., Fukumura D., Jain R.K. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 2012, 7:383-388.
253. Prabhakar U., Maeda H., Jain R.K., Sevick-Muraca E.M., Zamboni W., Farokhzad O.C., Barry S.T., Gabizon A., Grodzinski P., Blakey D.C. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013, 73:2412-2417.
254. Burgess D.J. Microenvironment: a dense danger. Nat. Rev. Cancer 2012, 12:656-657.
255. Maier U., Baumgartner G. Metaphylactic effect of mitomycin C with and without hyaluronidase after transurethral resection of bladder cancer: randomized trial. J. Urol. 1989, 141:529-530.
256. Smith K.J., Skelton H.G., Turiansky G., Wagner K.F. Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi's sarcoma. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). J. Am. Acad. Dermatol. 1997, 36:239-242.
257. Schumer J., Klocker J., Tidstrand J., Rab B., Allmayer H. Cisplatin, vindesine and hyaluronidase combined with simultaneous radiotherapy of advanced head and neck tumors. Onkologie 1990, 13:310-312.
258. Kohno N., Ohnuma T., Truog P. Effects of hyaluronidase on doxorubicin penetration into squamous carcinoma multicellular tumor spheroids and its cell lethality. J. Cancer Res. Clin. Oncol. 1994, 120:293-297.
259. Farr C., Menzel J., Seeberger J., Schweigle B. Clinical pharmacology and possible applications of hyaluronidase with reference to Hylase "Dessau". Wien. Med. Wochenschr. 1997, 147:347-355.
260. Brekken C., de Lange Davies C. Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner. Cancer Lett. 1998, 131:65-70.
261. Brekken C., Hjelstuen M.H., Bruland O.S., de Lange Davies C. Hyaluronidase-induced periodic modulation of the interstitial fluid pressure increases selective antibody uptake in human osteosarcoma xenografts. Anticancer Res. 2000, 20:3513-3519.
262. Eikenes L., Tari M., Tufto I., Bruland O.S., de Lange Davies C. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br. J. Cancer 2005, 93:81-88.
263. Provenzano P.P., Cuevas C., Chang A.E., Goel V.K., Von Hoff D.D., Hingorani S.R. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:418-429.
264. Eikenes L., Bruland O.S., Brekken C., Davies Cde L. Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res. 2004, 64:4768-4773.
265. McKee T.D., Grandi P., Mok W., Alexandrakis G., Insin N., Zimmer J.P., Bawendi M.G., Boucher Y., Breakefield X.O., Jain R.K. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 2006, 66:2509-2513.
266. Zheng X., Goins B.A., Cameron I.L., Santoyo C., Bao A., Frohlich V.C., Fullerton G.D. Ultrasound-guided intratumoral administration of collagenase-2 improved liposome drug accumulation in solid tumor xenografts. Cancer Chemother. Pharmacol. 2011, 67:173-182.
267. Muckenschnabel I., Bernhardt G., Spruss T., Buschauer A. Pharmacokinetics and tissue distribution of bovine testicular hyaluronidase and vinblastine in mice: an attempt to optimize the mode of adjuvant hyaluronidase administration in cancer chemotherapy. Cancer Lett. 1998, 131:71-84.
268. Patil Y.B., Toti U.S., Khdair A., Ma L., Panyam J. Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. Biomaterials 2009, 30:859-866.
269. Wong C., Stylianopoulos T., Cui J., Martin J., Chauhan V.P., Jiang W., Popovic Z., Jain R.K., Bawendi M.G., Fukumura D. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:2426-2431.
270. Cabral H., Matsumoto Y., Mizuno K., Chen Q., Murakami M., Kimura M., Terada Y., Kano M.R., Miyazono K., Uesaka M., Nishiyama N., Kataoka K. Accumulation of sub-100nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 2011, 6:815-823.
271. Goodman T.T., Olive P.L., Pun S.H. Increased nanoparticle penetration in collagenase-treated multicellular spheroids. Int. J. Nanomedicine 2007, 2:265-274.
272. Kuhn S.J., Finch S.K., Hallahan D.E., Giorgio T.D. Proteolytic surface functionalization enhances in vitro magnetic nanoparticle mobility through extracellular matrix. Nano Lett. 2006, 6:306-312.
273. Magzoub M., Jin S., Verkman A.S. Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin. FASEB J. 2008, 22:276-284.
274. Netti P.A., Berk D.A., Swartz M.A., Grodzinsky A.J., Jain R.K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000, 60:2497-2503.
275. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., Frese K.K., Denicola G., Feig C., Combs C., Winter S.P., Ireland-Zecchini H., Reichelt S., Howat W.J., Chang A., Dhara M., Wang L., Ruckert F., Grutzmann R., Pilarsky C., Izeradjene K., Hingorani S.R., Huang P., Davies S.E., Plunkett W., Egorin M., Hruban R.H., Whitebread N., McGovern K., Adams J., Iacobuzio-Donahue C., Griffiths J., Tuveson D.A. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
276. Jimeno A., Weiss G.J., Miller W.H., Gettinger S.N., Eigl B., Chang A.L., Dunbar J., Devens S., Faia K., Skliris G., Kutok J.L., Lewis K.D., Tibes R., Sharfman W.H., Ross R.W., Rudin C.M. Phase 1 study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin. Cancer Res. 2013, 19:2766-2774.
277. Diop-Frimpong B., Chauhan V.P., Krane S., Boucher Y., Jain R.K. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:2909-2914.